Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S158–S178
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Abstract
In the article cited above, the content in Table 9.2 regarding clinical considerations for the class of medications glucagon-like peptide 1 receptor agonists (GLP1-RAs) has been amended to reflect counseling patients about potential for ileus for all medications in this class. The original content for clinical considerations for GLP1-RAs appeared as follows:“Counsel patients about potential for ileus (semaglutide SQ)” The revised content for clinical considerations for GLP1-RAs now reads:“Counsel patients about potential for ileus” The online version of Section 9 (https://doi.org/10.2337/dc24-S009) has been updated with the revised text.